New York City-based Pfizer is considering the sale of several cardiology, urology and primary care treatments, a source told Bloomberg.
Here are four things to know.
1. Pfizer is working with financial advisors at JPMorgan Chase & Co., although the divestiture is still in a preliminary stage, the source said.
2. The drugs produce sales of more than $700 million and are valued at more than $2 billion, according to the report. About 40 percent of the sales occur in the U.S. and 45 percent occur in Europe.
3. Pfizer prefers to divest the medications through a single deal, as opposed to selling off each drug individually, reports Bloomberg.
4. Representatives from Pfizer and JPMorgan declined Bloomberg's request for comment.
More articles on supply chain:
This week's 5 must-reads for supply chain leaders
A new framework for measuring the true value of drugs: 5 takeaways
Bloomberg: Medtronic arranging sale of medical supplies business